Merck (MRK) Other Working Capital Changes (2009 - 2026)
Merck (MRK) posted quarterly Other Working Capital Changes of -$222.0 million for Q1 2011, down 237.89% year-over-year from $161.0 million in Q1 2010, and up 21.72% quarter-over-quarter from -$283.6 million in Q4 2010.
Merck (MRK) Other Working Capital Changes (2009 - 2026) Analysis & Trends
Merck (MRK) has reported Other Working Capital Changes for 3 consecutive years, with -$222.0 million the latest figure, recorded in Q1 2011.
- In Q1 2011, Other Working Capital Changes fell 237.89% year-over-year to -$222.0 million; the TTM figure through Mar 2011 stood at -$223.0 million (down 586.15% YoY), while the FY2025 annual figure was $3.3 billion, up 133.55% from the prior year.
- Other Working Capital Changes rose to -$222.0 million in Q1 2011 per MRK's latest filing, from -$283.6 million in the prior quarter.
- Across five years, Other Working Capital Changes topped out at $428.3 million in Q4 2009 and bottomed at -$321.5 million in Q2 2009.
- Historically, Other Working Capital Changes has averaged $989.7 million across 5 years, with a median of $1.4 billion in 2022.
- Annual changes were most pronounced in 2023 — Other Working Capital Changes slumped 727.76% — and 2025, when it jumped 123.22%.
- Merck's Other Working Capital Changes stood at $428.3 million in 2009, then plunged by 166.22% to -$283.6 million in 2010, then increased by 21.72% to -$222.0 million in 2011.
- Business Quant data shows MRK's Other Working Capital Changes at -$222.0 million in Q1 2011, -$283.6 million in Q4 2010, and $6.6 million in Q3 2010.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Johnson & Johnson | 652.20 Bn | 631.44 Bn | 17.26 Bn |
| 2 | AbbVie | 469.51 Bn | 462.94 Bn | 12.70 Bn |
| 3 | Merck | 376.81 Bn | 369.67 Bn | 12.21 Bn |
| 4 | Novartis Ag | 303.04 Bn | 295.35 Bn | 11.24 Bn |
| 5 | Astrazeneca | 257.61 Bn | 252.71 Bn | 12.86 Bn |
| 6 | Amgen | 237.37 Bn | 223.38 Bn | 7.24 Bn |
| 7 | Gilead Sciences | 181.73 Bn | 178.55 Bn | 6.22 Bn |
| 8 | Pfizer | 159.66 Bn | 147.96 Bn | 10.94 Bn |
| 9 | Gsk | 106.24 Bn | 102.07 Bn | 8.24 Bn |
| 10 | Sanofi | 55.07 Bn | 47.69 Bn | 10.79 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -423.00 Mn |
| Jun 30, 2026 | -423.00 Mn |
| Jun 30, 2026 | -423.00 Mn |
| Mar 31, 2026 | 1.61 Bn |
| Mar 31, 2026 | 1.61 Bn |
| Mar 31, 2026 | 1.61 Bn |
| Sep 30, 2025 | -1.31 Bn |
| Sep 30, 2025 | -1.31 Bn |
| Sep 30, 2025 | -1.31 Bn |
| Jun 30, 2025 | 2.26 Bn |
| Jun 30, 2025 | 2.26 Bn |
| Jun 30, 2025 | 2.26 Bn |
| Mar 31, 2025 | 3.71 Bn |
| Mar 31, 2025 | 3.71 Bn |
| Mar 31, 2025 | 3.71 Bn |
| Sep 30, 2024 | -2.58 Bn |
| Sep 30, 2024 | -2.58 Bn |
| Sep 30, 2024 | -2.58 Bn |
| Jun 30, 2024 | 1.01 Bn |
| Jun 30, 2024 | 1.01 Bn |